The IL-15-Based ALT-803 Complex Enhances FcγRIIIa-Triggered NK Cell Responses and in Vivo Clearance of B Cell Lymphomas

Clinical Cancer Research

Volumn 22, Issue 3, 2016, Pages 596-608

  Rosario, Maximillian ^a   Liu, Bai ^b   Kong, Lin ^b   Collins, Lynne I ^c   Schneider, Stephanie E ^a   Chen, Xiaoyue ^b   Han, Kaiping ^b   Jeng, Emily K ^b   Rhode, Peter R ^b   Leong, Jeffrey W ^a   Schappe, Timothy ^a   Jewell, Brea A ^a   Keppel, Catherine R ^a   Shah, Keval ^a   Hess, Brian ^a   Romee, Rizwan ^a   Piwnica Worms, David R ^c,d   Cashen, Amanda F ^a   Bartlett, Nancy L ^a   Wong, Hing C ^b   Fehniger, Todd A ^a   more..

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ALTOR BIOSCIENCE CORPORATION   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALT 803; ANTINEOPLASTIC AGENT; GAMMA INTERFERON; GRANZYME B; PERFORIN; RECOMBINANT INTERLEUKIN 15; RITUXIMAB; UNCLASSIFIED DRUG; ALT-803; FC RECEPTOR; FCGR3A PROTEIN, HUMAN; GRANZYME; PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B CELL LYMPHOMA; B LYMPHOCYTE ACTIVATION; CELL PROLIFERATION; CELL SURVIVAL; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG MECHANISM; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; IN VITRO STUDY; IN VIVO STUDY; INTERFERON PRODUCTION; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TUMOR CELL; ANIMAL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; BIOSYNTHESIS; CYTOTOXICITY; DISEASE MODEL; DRUG EFFECTS; DRUG POTENTIATION; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; KNOCKOUT MOUSE; LYMPHOMA, B-CELL; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; DISEASE MODELS, ANIMAL; DRUG SYNERGISM; GENE EXPRESSION REGULATION, NEOPLASTIC; GRANZYMES; HUMANS; INTERFERON-GAMMA; KILLER CELLS, NATURAL; LYMPHOMA, B-CELL; MICE; MICE, KNOCKOUT; PERFORIN; PROTEINS; RECEPTORS, IGG; RITUXIMAB; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84959036947     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-15-1419     Document Type: Article

References (54)

1. Winter JN, Gascoyne RD, Van Besien K. Low-grade lymphoma. Hematol 2004;203-20.
2. Freedman A. Follicular lymphoma: 2014 update on diagnosis and management. Am J Clin Pathol 2014;89:429-36.
3. Cheson BD, Leonard JP. Monoclonal antibody therapy for B-Cell nonhodgkin's lymphoma. N Engl J Med 2014;359:613-26.
4. Reeder CB, Ansell SM. Novel therapeutic agents for B-cell lymphoma: Developing rational combinations. Blood 2011;117:1453-62.
5. Younes A. Beyond chemotherapy: New agents for targeted treatment of lymphoma. Nat Rev Clin Oncol 2011;8:85-96.
6. Alderson KL, Sondel PM. Clinical cancer therapy by NK cells via antibodydependent cell-mediated cytotoxicity. J Biomed Biotechnol 2011; doi:10.1155/2011/379123.
7. Shuptrine C, Surana R, Weiner LM. Monoclonal antibodies for the treatment of cancer. Semin Cancer Biol 2012;22:3-13.
8. Caligiuri MA. Human natural killer cells. Blood 2008;112:461-9.
9. Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002;99: 754-8.
10. Weng W-K, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 2003;21:3940-7.
11. Fischer L, Penack O, Gentilini C, Nogai A, Muessig A, Thiel E, et al. The antilymphoma effect of antibody-mediated immunotherapy is based on an increased degranulation of peripheral blood natural killer (NK) cells. Exp Hematol 2006;34:753-9.
12. Veeramani S, Wang S-Y, Dahle C, Blackwell S, Jacobus L, Knutson T, et al. Rituximab infusion induces NK activation in lymphoma patients with the high-affinity CD16 polymorphism. Blood 2011;118:3347-9.
13. Du J, Lopez-Verges S, Pitcher B, Johnson J, Jung S, Zhou L, et al. CALGB 150905 (Alliance): Rituximab broadens the antilymphoma response by activating unlicensed NK cells. Cancer Immunol Res 2014;2:878-89.
14. Romee R, Leong JW, Fehniger TA. Utilizing cytokines to function-enable human NK cells for the immunotherapy of cancer. Scientifica (Cairo) 2014;10.1155/2014/205796.
15. Carson WE, Giri JG, Lindemann MJ, Linett ML, Ahdieh M, Paxton R, et al. Interleukin 15 is a novel cytokine that activates natural killer cells via components of the IL-2 receptor. J Exp Med 1994;180: 1395-403.
16. Moga E, Alvarez E, Cant-o E, Vidal S, Rodríguez-S-anchez JL, Sierra J, et al.NK cells stimulated with IL-15 or CpG ODN enhance rituximab-dependent cellular cytotoxicity against B-cell lymphoma. Exp Hematol 2008;36: 69-77.
17. Fehniger TA, Caligiuri MA. Interleukin 15: Biology and relevance to human disease. Blood 2001;97:14-32.
18. Waldmann TA. Interleukin-15 in the treatment of cancer. Expert Rev Clin Immunol 2014;10:1689-701.
19. Waldmann TA. The biology of interleukin-2 and interleukin-15: Implications for cancer therapy and vaccine design. Nat Rev Immunol 2006;6: 595-601.
20. Stoklasek TA, Schluns KS, Lefranc L. Combined IL-15/IL-15Ra immunotherapy maximizes IL-15 activity in vivo. J Immunol 2006;177: 6072-80.
21. Rubinstein MP, Kovar M, Purton JF, Cho J-H, Boyman O, Surh CD, et al. Converting IL-15 to a superagonist by binding to soluble IL-15Ralpha. Proc Natl Acad Sci U S A 2006;103:9166-71.
22. Mortier E, Qu-em-ener A, Vusio P, Lorenzen I, Boublik Y, Grotzinger J, et al. Soluble interleukin-15 receptor alpha (IL-15R alpha)-sushi as a selective and potent agonist of IL-15 action through IL-15R beta/gamma. Hyperagonist IL-15 x IL-15R alpha fusion proteins. J Biol Chem 2006;281:1612-9.
23. Zhu X, Marcus WD, Xu W, Lee H, Han K, Egan JO, et al. Novel human interleukin-15 agonists. J Immunol 2009;183:3598-607.
24. Han K, Zhu X, Liu B, Jeng E, Kong L, Yovandich JL, et al. IL-15:IL-15 receptor alpha superagonist complex: High-level co-expression in recombinant mammalian cells, purification and characterization. Cytokine 2011;56: 804-10.
25. Xu W, Jones M, Liu B, Zhu X, Johnson CB, Edwards AC, et al. Efficacy and mechanism-of-action of a novel superagonist interleukin-15: Interleukin-15 receptor aSu/Fc fusion complex in syngeneic murine models of multiple myeloma. Cancer Res 2013;73:3075-86.
26. Romee R, Schneider SE, Leong JW, Chase JM, Keppel CR, Sullivan RP, et al. Cytokine activation induces human memory-like NK cells. Blood 2012; 120:4751-60.
27. Leong JW, Chase JM, Romee R, Schneider SE, Sullivan RP, Cooper M a, et al. Preactivation with IL-12, IL-15, and IL-18 Induces CD25 and a functional high-affinity IL-2 receptor on human cytokine-induced memory-like natural killer cells. Biol Blood Marrow Transpl 2014; 20:463-73.
28. Fehniger TA, Cai SF, Cao X, Bredemeyer AJ, Presti RM, French AR, et al. Acquisition of murine NK cell cytotoxicity requires the translation of a pre-existing pool of granzyme B and perforin mRNAs. Immunity 2007;26:798-811.
29. Rettig MP, Ritchey JK, Prior JL, Haug JS, Piwnica-Worms D, DiPersio JF. Kinetics of in vivo elimination of suicide gene-expressing t cells affects engraftment, graft-versus-host disease, and graft-versus-leukemia after allogeneic bone marrow transplantation. J Immunol 2004; 173:3620-30.
30. Lopez-Verg-es S, Milush JM, Pandey S, York Va, Arakawa-Hoyt J, Pircher H, et al. CD57 defines a functionally distinct population of mature NK cells in the human CD56dimCD16+ NK-cell subset. Blood 2010;116:3865-74.
31. Molina A. A decade of rituximab: Improving survival outcomes in non-Hodgkin's lymphoma. Annu Rev Med 2008;59:237-50.
32. Czuczman MS, Leonard JP, Jung S, Johnson JL, Hsi ED, Byrd JC, et al. Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular lymphoma international prognostic index (FLIPI) score is predictive of upfront immunotherapy responsiveness. Ann Oncol 2012;23:2356-62.
33. Grant BW, Jung S-H, Johnson JL, Kostakoglu L, Hsi E, Byrd JC, et al. A phase 2 trial of extended induction epratuzumab and rituximab for previously untreated follicular lymphoma: CALGB 50701. Cancer 2013;119: 3797-804.
34. Wu L, Adams M, Carter T, Chen R, Muller G, Stirling D, et al. lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells. Clin Cancer Res 2008;14:4650-7.
35. Leonard J, Jung S-H, Johnson JL, Bartlett N, Blum KA, Cheson BD. CALGB 50401: A randomized trial of lenalidomide alone versus lenalidomide plus rituximab in patients with recurrent follicular lymphoma. J Clin Oncol 2012;30:A8000.
36. Tuscano JM, Dutia M, Chee K, Brunson A, Reed-Pease C, Abedi M, et al. Lenalidomide plus rituximab can produce durable clinical responses in patients with relapsed or refractory, indolent non-Hodgkin lymphoma. Br J Haematol 2014;165:375-81.
37. Hernandez-Ilizaliturri FJ, Deeb G, Zinzani PL, Pileri Sa, Malik F, Macon WR, et al. Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype. Cancer 2011;117:5058-66.
38. Khan KD, Emmanouilides C, Benson DM, Hurst D, Garcia P, Michelson G, et al. A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin's lymphoma. Clin Cancer Res 2006;12:7046-53.
39. Berdeja JG, Hess A, Lucas DM, O'Donnell P, Ambinder RF, Diehl LF, et al. Systemic interleukin-2 and adoptive transfer of lymphokine-activated killer cells improves antibody-dependent cellular cytotoxicity in patients with relapsed B-cell lymphoma treated with rituximab. Clin Cancer Res 2007;13:2392-9.
40. Ansell SM, Geyer SM, Maurer MJ, Kurtin PJ, Micallef INM, Stella P, et al. Randomized phase II study of interleukin-12 in combination with rituximab in previously treated non-Hodgkin's lymphoma patients. Clin Cancer Res 2006;12:6056-63.
41. Timmerman JM, Byrd JC, Andorsky DJ, Yamada RE, Kramer J, Muthusamy N, et al. A phase I dose-finding trial of recombinant interleukin-21 and rituximab in relapsed and refractory low grade B-cell lymphoproliferative disorders. Clin Cancer Res 2012;18:5752-60.
42. Robertson MJ, Kline J, Struemper H, Koch KM, Bauman JW, Gardner OS, et al. A dose-escalation study of recombinant human interleukin-18 in combination with rituximab in patients with non-hodgkin lymphoma. J Immunother 2013;36:331-41.
43. Jaime-Ramirez AC, Mundy-Bosse BL, Kondadasula S, Jones NB, Roda JM, Mani A, et al. IL-12 enhances the antitumor actions of trastuzumab via NK cell IFN-g production. J Immunol 2011;186:3401-9.
44. Roda JM, Joshi T, Butchar JP, McAlees JW, Lehman A, Tridandapani S, et al. The activation of natural killer cell effector functions by cetuximab-coated, epidermal growth factor receptor positive tumor cells is enhanced by cytokines. Clin Cancer Res 2007;13:6419-28.
45. Luedke E, Jaime-Ramirez AC, Bhave N, Roda J, Choudhary MM, Kumar B, et al. Cetuximab therapy in head and neck cancer: Immune modulation with interleukin-12 and other natural killer cell-activating cytokines. Surgery 2012;152:431-40.
46. Roda JM, Parihar R, Iii WEC, Cells T, Roda JM, Parihar R, et al. Enhance the NK cell cytokine response to antibody-coated. J Immumol 2005;175: 1619-27.
47. Koreth J, Matsuioka K, Kim H, Mcdonough SM, Bindra B, Alyea EP, et al. Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med 2013;365:2055-66.
48. Westin JR, Chu F, Zhang M, Fayad LE, Kwak LW, Fowler N, et al. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: A single group, open-label, phase 2 trial. Lancet Oncol 2014;15:69-77.
49. Gill S, June CH. Going viral: Chimeric antigen receptor T-cell therapy for hematological malignancies. Immunol Rev 2015;263:68-89.
50. Kochenderfer JN, Dudley ME, Kassim SH, Somerville RPT, Carpenter RO, Stetler-Stevenson M, et al. Chemotherapy-refractory diffuse large B-cell lymphomaand indolent B-Cell malignancies can be effectively treated with autologous T cells expressing an Anti-CD19 chimeric antigen receptor. J Clin Oncol 2015;33:540-9.
51. Conlon KC, Lugli E, Welles HC, Rosenberg Sa, Fojo AT, Morris JC, et al. Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer. J Clin Oncol 2015;33:74-82.
52. Bhat R,Watzl C. Serial killing of tumor cells by human natural killer cells-enhancement by therapeutic antibodies. PLoS ONE 2007;2:e326.
53. Abes R, Gelize E, WH F, Teillaud J. Long-lasting antitumor protection by anti-CD20 antibody through cellular immune response. Blood 2010;116: 926-35.
54. Hilchey SP, Hyrien O, Mosmann TR, Livingstone AM, Friedberg JW, Young F, et al. Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: SuPpOrT FoR A "vAcCinal effect" of rituximab (brief report). Blood 2014; 113:3809-13.